Medix Biochemica

‍What is Medix Biochemica?

Medix Biochemica is a global leader in development and manufacturing of critical components for the in vitro diagnostics industry. In addition, it offers diagnostic tests with focus on the women’s health sector. The company was founded in 1985 and it currently employs about 267 people in its locations in Europe, the US and China. Medix Biochemica has a strict focus on quality - it has an ISO 13485 certificate and its operations are also FDA QSR compliant.

‍Why did we invest in Medix Biochemica?

DevCo has, for a long time, regarded in vitro diagnostics (IVD) as a fundamentally attractive growth market which is supported by strong global trends such as aging of population. Furthermore, tests continue to improve as a result of continuous research. Following a careful review of the IVD sector and several companies operating in it, Medix Biochemica was seen as a particularly attractive platform company for DevCo, due to its attractive value chain position as a developer and provider of critical components for diagnostic tests, excellent reputation among customers in all regions, and high quality of its in vitro manufacturing operations. In addition to significant organic growth potential in the long term, DevCo sees opportunities for Medix Biochemica to drive consolidation in its markets as part of its strategy to become the #1 choice in IVD.

‍
Impact on society

As a global pioneer in monoclonal antibodies for the IVD industry, Medix Biochemica has to date provided critical components for more than 10 billion laboratory tests in all major regions.